Print

A new breast cancer drug improves overall survival among people with brain and other metastases

https://www.facingourrisk.org/XRAY/new-drug-improves-outcomes-for-metastatic-breast-cancer

A promising new drug called tucatinib combined with standard therapy shows benefit for women with HER2-positive metastatic breast cancer. Women who took tucatinib experienced longer progression-free survival (time before their cancer worsened), longer overall survival time and response of cancer (shrinking or disappearing). Strikingly, better outcomes were also seen for women with brain metastases, which is often difficult to treat. (12/20/19) 

THIS INFORMATION HAS BEEN UPDATED on 04/17/20:  The U.S. Food and Drug Administration has approved Tukysa (tucatinib) for use in combination with trastuzumab (Herceptin) and capecitabine for patients with advanced or metastatic HER2-positive breast cancer, including patients with brain metastases (disease that has spread to the brain). Patients who have received one or more treatments targeting Her2 in the metastic setting are eligible to receive Tukysa. Tukysa  is an oral (tablet) tyrosine kinase inhibitor which is taken twice daily. 

 

 

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following are studies looking at treatment for people with metastatic HER2-positive breast cancer.  

Other clinical trials for people with breast cancer can be found here.

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.